Background First-line controller combination therapy for the management of asthma is a low-
dose inhaled corticosteroid (LD-ICS)+ a long-acting β-agonist (LABA), and second-line …

Asthma is a chronic lung disease characterized by reversible airway obstruction,
inflammation, and increased airway responsiveness. There are currently two categories of …

Background Most randomized trials of treatment for asthma study highly selected patients
under idealized conditions. Methods We conducted two parallel, multicenter, pragmatic trials …

Combination therapies with inhaled corticosteroids (ICS) and either long-acting β2 agonists
(LABA) or leukotriene receptor antagonists (LTRA) are commonly used to help patients …

The severity of asthma often varies throughout the course of the disease. At times the
symptoms and underlying inflammation that are characteristic of asthma can worsen. Thus …

Objective To review the evidence for the use of open-inhaler (inhaled corticosteroid [ICS]
plus long-acting β2-agonist [LABA] with separate add-on long-acting muscarinic antagonist …

Drug Class Review: Controller Medications for Asthma: Final Update 1 Report - Abstract -
Europe PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools …

The asthma syndrome is characterised by airway inflammation with associated bronchial
hyperresponsiveness (BHR) and reversible airflow obstruction. Therapy has benefited from …

Introduction Inhaled corticosteroid/long-acting β2-adrenoceptor agonist/long-acting
muscarinic antagonist (ICS/LABA/LAMA) fixed-dose combination (FDC) is currently …

Symptom control in patients with moderate to severe persistent asthma is essential to reduce
the significant morbidity associated with the disease. Poor adherence to controller …